Condition: Intra Cerebral Hemorrhage · Sponsor: Insel Gruppe AG, University Hospital Bern
The MAX-ICH pilot trial is a phase-II study aimed at assessing the feasibility and safety of a comprehensive care bundle for patients with intracerebral hemorrhage (ICH). This "maximal medical treatment" approach combines advanced interventions like intensive blood pressure control, rapid anticoagulation reversal, and tranexamic acid administration to potentially improve outcomes. The primary objective is to evaluate recruitment feasibility over 12 months, while secondary objectives include protocol adherence, safety monitoring, and the exploration of clinical outcomes. The study focuses on the critical first 72 hours of care to determine if this approach can be effectively implemented in clinical practice.
This description comes directly from the study's public registry record.
David J Seiffge, Prof. Dr. med. · +41 31 66 40 509 · david.seiffge@insel.ch
Bernhard M Siepen, Dr. med. · +41 31 63 24 220 · bernhard.siepen@insel.ch
Always discuss trial participation with your own doctor first.
| Inselspital, University Hospital Bern | Bern, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06648369